YK-4-279 is primarily used in biomedical research as an inhibitor of protein-protein interactions involving the EWS-FLI1 fusion protein, which is associated with Ewing sarcoma. It has shown potential in disrupting the binding between EWS-FLI1 and RNA helicase A, leading to reduced tumor cell proliferation and induction of apoptosis in cancer cells. Due to this mechanism, YK-4-279 serves as a valuable tool compound for studying oncogenic transcription factors and developing targeted cancer therapies. Its application extends to preclinical studies evaluating the efficacy of small molecules in blocking aberrant transcriptional activity in sarcomas and other cancers driven by similar fusion oncoproteins.